The clearest non-tech momentum signal on Tuesday is Caterpillar. Its rally is backed by record revenue, a large earnings beat and higher full-year expectations. BP and Pfizer also delivered better-than-expected results, but their smaller price reactions make them confirmation trades rather than clean breakouts.
The useful distinction is not simply which company reported a profit beat. It is whether the result changed the forward outlook—and whether investors are willing to keep paying for that change after the opening reaction.
Market snapshot
Prepared Tuesday, August 4, 2026, at 3:18 p.m. BST / 10:18 a.m. ET. The latest reliably verified public reports available during drafting showed:
- the S&P 500 up roughly 0.4%–0.6%;
- the Dow up roughly 1.2%–1.3%, helped heavily by Caterpillar;
- the Nasdaq up roughly 1.0%–1.1%;
- Brent crude near $80–$81 a barrel after another sharp decline;
- the U.S. 10-year Treasury yield near 4.63%.
These are intraday observations, not closing data. Prices and percentages can change materially before the 4:00 p.m. ET close.
1. Caterpillar: the strongest earnings-backed move
Caterpillar reported second-quarter revenue of $20.54 billion, up 24% year over year and above market expectations. Adjusted earnings reached $8.17 per share, compared with an estimate near $6.22, while net income rose to $3.59 billion.
The strength was broad rather than confined to one division:
- Construction Industries sales rose 35% to $8.35 billion.
- Power and Energy sales rose 17% to $8.24 billion.
- Resource Industries sales rose 20% to $4.65 billion.
Management upgraded its full-year revenue-growth outlook to the mid-to-high teens, from a previous expectation of low double-digit growth. The shares rose roughly 9%–11% in early indications and trading.
Catalyst: sustained equipment orders, infrastructure activity and demand for power-generation systems.
Evidence: record quarterly revenue, a wide earnings beat, growth across all three major operating divisions and higher annual guidance.
Main risk: Caterpillar remains cyclical. Tariff costs are expected to reach about $2.2 billion this year, while construction, mining and energy demand can weaken quickly if financing conditions or capital spending deteriorate.
Invalidation condition: the setup weakens if Caterpillar gives back most of the earnings gap and closes near or below Monday’s level, especially if analysts reduce estimates or management’s upgraded outlook proves dependent on temporary pricing rather than durable volume.
2. BP: strong cash generation, but the catalyst belongs to oil
BP’s underlying replacement-cost profit rose to $5.73 billion, more than double the year-earlier result and above analyst expectations. The company also raised its dividend by 4%. BP shares gained around 1%–1.5% in London and early U.S. trading indications.
The result was supported by higher energy prices, strong oil trading and improved refining margins during disruption linked to the U.S.–Iran conflict. BP is also accelerating a strategic reset under its new chief executive, including asset sales and a renewed emphasis on oil and gas.
Catalyst: continued strength in trading and refining, successful asset disposals and more consistent operating execution.
Evidence: the profit beat, dividend increase and highest quarterly profit since 2022 provide real financial support for the move.
Main risk: this is the most commodity-dependent setup of the three. Oil prices were already falling sharply on Tuesday, and BP reported weaker upstream reliability and lower output. Higher planned capital spending also raises the execution bar.
Invalidation condition: the momentum case weakens if BP loses its earnings gain while crude remains firm, or if falling oil and refining margins reveal that the quarter’s cash generation cannot be sustained through a more normal pricing environment.
3. Pfizer: a credible beat, but not yet a momentum breakout
Pfizer reported adjusted earnings of $0.77 per share on revenue of $15.03 billion, ahead of expectations near $0.68 and $14.4 billion. The company raised its 2026 sales outlook by $500 million to $60.5 billion–$62.5 billion while maintaining adjusted earnings guidance of $2.80–$3.00 per share.
The shares moved only slightly higher in premarket trading, near $25.20 in one public report. That restrained reaction matters: the operating update improved, but investors have not yet treated it as a major change in Pfizer’s longer-term growth story.
Catalyst: additional upward sales revisions, better product-level growth and evidence that acquisitions strengthen rather than dilute future earnings.
Evidence: Pfizer beat both revenue and adjusted-profit expectations and raised its annual sales range.
Main risk: the guidance increase is modest, and the company’s Innovent Biologics acquisition is expected to reduce 2026 earnings by about $0.10 per share. A one-quarter beat does not by itself resolve the market’s concerns about future product growth.
Invalidation condition: the setup fails if Pfizer loses the earnings-day gain and management later cuts the revised sales range, or if new and acquired products do not offset weaker areas of the portfolio.
Momentum ranking
| Stock | Quality of evidence | Price confirmation | Main dependency |
|---|---|---|---|
| Caterpillar | Strongest: record revenue, broad segment growth and raised guidance | Strong | Orders, infrastructure spending and tariff control |
| BP | Strong profit and dividend evidence | Moderate | Oil prices, refining margins and execution |
| Pfizer | Beat-and-raise, but the outlook change is small | Weakest | Product growth and acquisition returns |
What could sustain the moves
For Caterpillar, the most constructive signal would be holding most of the earnings gap through the close and continuing to outperform on a weaker market day. BP needs its strategic reset and cash returns to matter even when oil is not rising. Pfizer needs estimate increases and follow-through buying rather than another brief earnings bounce.
Conclusion
Caterpillar has Tuesday’s best combination of catalyst, evidence and market confirmation. BP’s earnings are strong, but the durability of the move depends heavily on commodity conditions. Pfizer delivered a respectable beat and higher sales outlook, yet its muted reaction shows that investors still want proof of longer-term growth.
Momentum is strongest when the price move and the forward business evidence agree. Today, Caterpillar clearly passes that test. BP and Pfizer still need follow-through.
Educational disclaimer: This article is for informational and educational purposes only. It is not financial advice, investment research or a recommendation to buy or sell any security. Intraday prices can reverse quickly, earnings gaps can close without warning, and commodity-sensitive stocks carry additional headline risk.
Sources
- Associated Press — U.S. stocks approach records as corporate profits rise, August 4, 2026
- Barron’s — Dow and S&P 500 open near record highs, August 4, 2026
- Caterpillar Investor Relations — Quarterly results
- MarketWatch — Caterpillar reports record revenue and raises its outlook, August 4, 2026
- Reuters — BP’s quarterly profit more than doubles, August 4, 2026
- Pfizer Investor Relations — Second-quarter 2026 performance webcast and materials
- Investor’s Business Daily — Pfizer beats estimates and raises its sales outlook, August 4, 2026